Table 3: Descriptive data and blood sample data for nondiabetic controls and patients with type 2 diabetes with or without statin treatment. Comparisons were made within groups, that is, nondiabetic controls with statin treatment versus nondiabetic controls without statin treatment and type 2 diabetes patients with statin treatment versus type 2 diabetes patients without statin treatment. HbA1c levels are given as NGSP (%) with IFCC values (mmol/mol) in parenthesis.

Variable Nondiabetic
statins (n = 4)
Nondiabetic
no statins (n = 14)
Type 2 diabetes
statins (n = 14)
Type 2 diabetes
no statins (n = 13)

Age (years)64.8 ± 2.765.6 ± 1.961.3 ± 2.162.6 ± 2.9
Weight (kg)81.1 ± 9.790.9 ± 6.484.3 ± 4.895.4 ± 2.4
BMI (kg/m2)27.3 ± 1.8 29.5 ± 1.729.0 ± 1.731.4 ± 1.6
Waist (cm)96.2 ± 7.8 103.7 ± 4.4102.0 ± 4.6107.0 ± 3.8
Hip (cm)105.4 ± 4.7 109.1 ± 3.6110.5 ± 4.7112.3 ± 3.8
Waist-hip ratio0.91 ± 0.05 0.87 ± 0.070.96 ± 0.030.98 ± 0.04
Fasting plasma cholesterol (mmol/L)6.25 ± 0.79 6.16 ± 0.294.30 ± 0.274.85 ± 0.20
Fasting plasma HDL cholesterol (mmol/L)1.35 ± 0.18 1.49 ± 0.111.16 ± 0.081.19 ± 0.06
Fasting plasma LDL cholesterol (mmol/L)4.10 ± 0.68 3.95 ± 0.232.44 ± 0.233.16 ± 0.14*
Fasting plasma triacylglycerols (mmol/L)1.82 ± 0.39 1.46 ± 0.171.52 ± 0.221.37 ± 0.10
Fasting plasma betatrophin (pg/mL)542 ± 77 666 ± 82858 ± 102930 ± 130
HbA1c
(% (mmol/mol))
5.9 ± 0.2
(40.8 ± 2.1)
5.8 ± 0.1
(39.9 ± 0.8)
6.8 ± 0.2
(50.9 ± 2.5)
6.7 ± 0.2
(50.4 ± 2.1)
Fasting plasma glucose mmol/L6.7 ± 0.4 6.0 ± 0.28.5 ± 0.6 8.5 ± 0.5

P < 0.05.